Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Supratentorial diffuse low-grade gliomas present a slow macroscopic tumor growth that can be quantified through the measurement of their velocity of diametric expansion. We assessed whether spontaneous velocity of diametric expansion can predict long-term outcomes as a categorical variable and as a continuous predictor. METHODS: A total of 407 adult patients with newly diagnosed supratentorial diffuse low-grade gliomas in adults were studied. RESULTS: The mean spontaneous velocity of diametric expansion before first-line treatment was 5.8 ± 6.3 mm/year. During the follow-up (mean, 86.5 ± 59.4 months), 209 patients presented a malignant transformation, and 87 died. The malignant progression-free survival and the overall survival were significantly longer in cases of slow velocity of diametric expansion (median, 103 and 249 months, respectively) than in cases of fast velocity of diametric expansion (median, 35 and 91 months, respectively; P < .001). In multivariate analyses, spontaneous velocity of diametric expansion as a categorical variable (<4, ≥4 and <8, ≥8 and <12, ≥12 mm/year) was an independent prognostic factor for malignant progression-free survival (P < .001; hazard ratio, 3.87; 95% confidence interval [CI], 2.67-5.52) and for overall survival (P < .001; hazard ratio, 4.62; 95% CI, 2.58-7.97). Velocity of diametric expansion was also an independent prognostic factor for overall survival as a continuous predictor, showing a linear relationship between overall survival and spontaneous velocity of diametric expansion (hazard ratio, 1.09 per one unit increase; 95% CI, 1.06-1.12; P < .001). CONCLUSIONS: Independent of the molecular status, the spontaneous velocity of diametric expansion allows the identification of rapidly growing diffuse low-grade gliomas (at higher risk of worsened evolution) during the pretherapeutic period and without delaying treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“VDE, the rate of change in tumor diameter over time, is an independent predictor of outcome in LGGs [43,44,45].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
— Tumors of the Central Nervous System
(2013) · Pediatric Radiotherapy Planning and Treatment · doi:10.1201/b14554-7 · Cited by 1,751
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
Sanai, N., & Berger, M. S. (2008) · Neurosurgery · doi:10.1227/01.neu.0000318159.21731.cf · Cited by 1,328 · cited 7×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
BackgroundInfluentialSelf-citationRole of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Smith, J. S., Chang, E. F., Lamborn, K. R., Chang, S. M., Prados, M. D., Cha, S., Tihan, T., VandenBerg, S., McDermott, M. W., & Berger, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9337 · Cited by 1,283 · cited 9×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
InfluentialPrognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955 · cited 1×
“2 mm over a 3-month period) should be considered as high-risk patients together with those without IDH mutation and those with known risk factors according to Pignatti and Chang scoring systems.(20,27) Because these LGGs share outcomes similar to those of malignant gliomas, treatment modalities should be selected acco…”
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505 · cited 1×
“Early maximal safe resection while preserving eloquent brain areas with use of perioperative functional monitoring is currently considered as the first-line treatment option.(3,8) Indeed, there is a growing trend that the extent of resection is a significant prognostic factor for malignant progression-free survival an…”
Self-citationContinuous growth of mean tumor diameter in a subset of grade II gliomas
Mandonnet, E., Delattre, J., Tanguy, M., Swanson, K. R., Carpentier, A. F., Duffau, H., Cornu, P., Van Effenterre, R., Alvord, E. C., & Capelle, L. (2003) · Annals of Neurology · doi:10.1002/ana.10528 · Cited by 493 · cited 1×
“It has previously been reported that LGGs demonstrate a spontaneous velocity of diametric expansion of 4 mm/year before and after surgical resection.(4,14) Of interest, velocity of diametric expansion changes after oncological treatment can predict outcomes in response to chemotherapy and radiotherapy.”
Self-citationPallud, J., Mandonnet, E., Duffau, H., Kujas, M., Guillevin, R., Galanaud, D., Taillandier, L., & Capelle, L. (2006) · Annals of Neurology · doi:10.1002/ana.20946 · Cited by 250 · cited 8×
“This pioneer study addressed only the prognostic significance on overall survival of velocity of diametric expansion as a categorical variable in a subset of 143 LGGs.6 It appears to be logical that the higher the velocity of diametric expansion is, the worse the outcomes are.”
InfluentialSelf-citationSwanson, K. R., Rockne, R. C., Claridge, J., Chaplain, M. A., Alvord, E. C., & Anderson, A. R. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1399 · Cited by 236 · cited 1×
“Accordingly, cell density in such tumors may not be high enough to generate hypoxic foci triggering neoangiogenesis and may lead to a LGG appearance on pathological examination.(28) Indeed, pathological findings do not exhibit significant differences in the spontaneous velocity of diametric expansion.”
Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities
Pallud, J., Varlet, P., Devaux, B., Geha, S., Badoual, M., Deroulers, C., Page, P., Dezamis, E., Daumas-Duport, C., & Roux, F.-X. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e04264 · Cited by 222 · cited 1×
“The anatomical distribution of LGG can be visualized on conventional magnetic resonance imaging (MRI) using T2-weighted or fluid attenuated inversion recovery sequences.(11) The subtle imaging changes over time reflect the macroscopic tumor growth.”
Self-citationSurgery of low-grade gliomas: towards a ‘functional neurooncology’
Duffau, H. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283305996 · Cited by 220
Self-citationDynamic history of low‐grade gliomas before and after temozolomide treatment
Ricard, D., Kaloshi, G., Amiel‐Benouaich, A., Lejeune, J., Marie, Y., Mandonnet, E., Kujas, M., Mokhtari, K., Taillibert, S., Laigle‐Donadey, F., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21125 · Cited by 207 · cited 8×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
InfluentialSelf-citationPrognostic significance of imaging contrast enhancement for WHO grade II gliomas
Pallud, J., Capelle, L., Taillandier, L., Fontaine, D., Mandonnet, E., Guillevin, R., Bauchet, L., Peruzzi, P., Laigle-Donadey, F., Kujas, M., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-066 · Cited by 200
Self-citationNatural history of incidental world health organization grade II gliomas
Pallud, J., Fontaine, D., Duffau, H., Mandonnet, E., Sanai, N., Taillandier, L., Peruzzi, P., Guillevin, R., Bauchet, L., Bernier, V., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22106 · Cited by 194
Self-citationTwo types of chromosome 1p losses with opposite significance in gliomas
Idbaih, A., Marie, Y., Pierron, G., Brennetot, C., Hoang-Xuan, K., Kujas, M., Mokhtari, K., Sanson, M., Lejeune, J., Aurias, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20607 · Cited by 167 · cited 7×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
InfluentialUpdate on molecular findings, management and outcome in low-grade gliomas
Bourne, T. D., & Schiff, D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.159 · Cited by 157 · cited 1×
“Molecular marker assessment, particularly 1p19q codeletion, p53 expression, and isocitrate dehydrogenase mutation, has improved the diagnosis accuracy and refined prognosis.(19) In addition, spontaneous velocity of diametric expansion was shown to represent an independent prognostic parameter for overall survival with…”
Pallud, J., Taillandier, L., Capelle, L., Fontaine, D., Peyre, M., Ducray, F., Duffau, H., & Mandonnet, E. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31826213de · Cited by 135
Self-citationMandonnet, E., Pallud, J., Clatz, O., Taillandier, L., Konukoğlu, E., Duffau, H., & Capelle, L. (2008) · Neurosurgical Review · doi:10.1007/s10143-008-0128-6 · Cited by 129 · cited 3×
“Indeed, within the framework of proliferation-diffusion models, the velocity of diametric expansion is proportional to the square root of the product of proliferation rates and cell diffusion coefficient.(13) Therefore, tumors with fast spontaneous velocity of diametric expansion, despite mild proliferation rates, sho…”
MethodSelf-citationPregnancy increases the growth rates of world health organization grade II gliomas
Pallud, J., Mandonnet, E., Deroulers, C., Fontaine, D., Badoual, M., Capelle, L., Guillet‐May, F., Page, P., Peruzzi, P., Jouanneau, E., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21888 · Cited by 108 · cited 1×
“However, additional extrinsic factors might affect LGG growth, as suggested by the negative impact of pregnancy.(30)”
Self-citationBrasil Caseiras, G., Ciccarelli, O., Altmann, D. R., Benton, C. E., Tozer, D. J., Tofts, P. S., Yousry, T. A., Rees, J., Waldman, A. D., & Jäger, H. R. (2009) · Radiology · doi:10.1148/radiol.2532081623 · Cited by 100
Peyre, M., Cartalat-Carel, S., Meyronet, D., Ricard, D., Jouvet, A., Pallud, J., Mokhtari, K., Guyotat, J., Jouanneau, E., Sunyach, M.-P., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq055 · Cited by 95
Self-citationChang, E. F., Clark, A., Jensen, R. L., Bernstein, M., Guha, A., Carrabba, G., Mukhopadhyay, D., Kim, W., Liau, L. M., Chang, S. M., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2009.2.jns081101 · Cited by 88 · cited 2×
“neurological deficit, increased intracranial pressure, Karnofsky performance status, and Chang score.(20) The recorded imaging characteristics gathered from longitudinal MRI follow-up included number of cerebral lobes involved, corpus callosum involvement, anatomical location, contrast enhancement,(21) and tumor volum…”
BackgroundMandonnet, E., Pallud, J., Fontaine, D., Taillandier, L., Bauchet, L., Peruzzi, P., Guyotat, J., Bernier, V., Baron, M.-H., Duffau, H., et al. (2009) · Neurosurgical Review · doi:10.1007/s10143-009-0229-x · Cited by 76 · cited 2×
“Here, we did not consider low-grade progression as an end point, because imaging follow-up was not uniform among all the cases in this series and because LGGs in adults are known to show a spontaneous growth in absence of oncological treatment and after surgery.(14) With regard to malignant progression-free survival,…”
Self-citationHlaihel, C., Guilloton, L., Guyotat, J., Streichenberger, N., Honnorat, J., & Cotton, F. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9991-4 · Cited by 71 · cited 1×
“previously demonstrated that an elevated velocity of diametric expansion was associated with a greater risk of malignant transformation.(24) Brasil Caseiras et al.”
Self-citationPallud, J., Llitjos, J.-F., Dhermain, F., Varlet, P., Dezamis, E., Devaux, B., Souillard-Scemama, R., Sanai, N., Koziak, M., Page, P., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos069 · Cited by 69
Self-citationTumors of the Central Nervous System
Shiminski‐Maher, T. (2012) · Springer eBooks · doi:10.1007/978-3-642-32554-0_6 · Cited by 61
1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth
Gozé, C., Bezzina, C., Gozé, É., Rigau, V., Maudelondé, T., Bauchet, L., & Duffau, H. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0831-6 · Cited by 49 · cited 8×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
InfluentialSelf-citationComment on Parameters of Low-Grade Glioma as Predictors
Pallud, J., Capelle, L., & Mandonnet, E. (2010) · Radiology · doi:10.1148/radiol.100299 · Cited by 15
Self-citationUsing mathematical modeling to predict survival of low‐grade gliomas
Alvord, E. C., & Swanson, K. R. (2007) · Annals of Neurology · doi:10.1002/ana.21042 · Cited by 8 · cited 1×
“If the 8 mm/year cutoff is easier in clinical practice to identify patients with an LGG at higher risk of worsened evolution, we identified a continuous gradation of velocity of diametric expansion contributing to survival differences (including malignant progressionfree survival and overall survival) in this large se…”
Letter to the Editor: Diffuse low-grade gliomas
Jakola, A. S., Unsgård, G., Kloster, R., & Solheim, O. S. (2013) · Journal of neurosurgery · doi:10.3171/2013.4.jns13859 · Cited by 5
Diffuse Low-Grade Gliomas: What Does “Complete Resection” Mean?
Pallud, J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0618-7_17 · Cited by 4 · cited 7×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
BackgroundInfluentialSelf-citationBerger (1994) · doi:10.1002/1097-0142(19940915)74:6<1784::aid-cncr2820740622>3.0.co;2-d
Research works printed but not linked: 2
- Reifenberger, 2007, Oligodendroglioma, 54
- von Deimling, 2007, Diffuse astrocytomas, 25
Cited by
Duffau, H., & Taillandier, L. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou153 · Cited by 281
Self-citationYoussef, G., & Miller, J. J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01040-8 · Cited by 165
Schiff, D., van den Bent, M. J., Vogelbaum, M. A., Wick, W., Miller, C. R., TAPHOORN, M. J. B., Pope, W. B., Brown, P. D., Platten, M., Jalali, R., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz033 · Cited by 140
López, P. D. D., Corrales-García, E. M., Martino, J., Aras, E. L., & Dueñas-Polo, M. T. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1631-4 · Cited by 136
“According to some studies, LGGs grow continuously over time at a steady rate of about 4–5 mm per year [27].”
BackgroundVerburg, N., Koopman, T., Yaqub, M. M., Hoekstra, O. S., Lammertsma, A. A., Barkhof, F., Pouwels, P. J. W., Reijneveld, J. C., Heimans, J. J., Rozemuller, A. J. M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz180 · Cited by 109
“22,23 Diffuse gliomas can be subclassified using different biomarkers—for example, imaging markers such as enhancement on T1G MRI, histopathological markers like the World Health Organization (WHO) classification, or molecular markers such as isocitrate dehydrogenase (IDH) mutational status.”
Metadata
- Authors
- Pallud, J., Blonski, M., Mandonnet, E., Audureau, E., Fontaine, D., Sanai, N., Bauchet, L., Peruzzi, P., Frénay, M., Colin, P., Guillevin, R., Bernier, V., Baron, M.-H., Guyotat, J., Duffau, H., Taillandier, L., & Capelle, L.
- Affiliations
- Barrow Neurological Institute (US)
- Corresponding author
- Pallud, Johan
- ORCID
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-07
- Volume
- 15
- Issue
- 5
- Pages
- 595-606
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC3635513
- OpenAlex
- W2160995760
- Cited by
- 173
- References
- 33
- Citations by year
- 2026: 5 · 2025: 18 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 17 · 2019: 15 · 2018: 16 · 2017: 24 · 2016: 5 · 2015: 11 · 2014: 11 · 2013: 4
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuro-Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- diffuse low-grade glioma, tumor growth rate, malignant transformation, prognostic factors, progression-free survival, overall survival, supratentorial glioma, adult glioma
- MeSH terms
- Adolescent, Adult, Aged, Brain Neoplasms, Female, Follow-Up Studies, Glioma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Survival Rate, Tumor Burden, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.